| Product | Indication | Dosage form | Strength |
|---|---|---|---|
| Depression | Tablets | 10 and 20 mg | |
| Buprenorphine | Opioid dependence | 0,4/ 1/ 2/ 4/ 6 & 8 mg sublingual films | |
| Eslicarbazepine | Epilepsy | Tablets | 400 and 1200 mg |
| Lamotrigine | Lamotrigine | XR tablets | 25/ 50/ 100/ 200 & 300 mg |
| Pyridostigmine | Myasthenia gravis | Film-coated tablets | 60 mg |
| Pyridostigminie | Myasthenia gravis | XR tablets | 180 mg |
| Quetiapine * | Psychosis, schizophrenia, bipolar disoder | Orodispersable tablets | 25 and 50 mg |
| Rotigotine | Parkinson disease & restless legs | Patches | 1, 2, 3, 4, 6 and 8 mg/24h |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.